Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat ovarian cancer: drug combo shows promise in early trial

NCT ID NCT05483933

Completed Disease control Sponsor: Shattuck Labs, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also looked for signs that the tumors shrank. The study is now complete, and results will help guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma primary peritoneal carcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER OVARIAN CANCER PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA PLATINUM-RESISTANT OVARIAN CANCER PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

  • BC Cancer Center

    Vancouver, British Columbia, BC V5Z 4E6, Canada

  • City of Hope

    Duarte, California, 91010, United States

  • Guy's & St Thomas' NHS Foundation Trust

    London, SE1 7EH, United Kingdom

  • Hospital Clinic de Barcelona Servicio de Oncología, Esc. 2, Planta 5 dcha

    Barcelona, Catalonia, 08036, Spain

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, 08916, Spain

  • Hospital Universitari Vall D Hebron

    Madrid, 28013, Spain

  • Hospital Universitario Dr. Josep Trueta - ICO de Girona, Servicio de Oncología Av. Francia s/n

    Girona, 17007, Spain

  • Hospital Universitario Fundacion Jimenez Diaz START Madrid-FJD- Unidad de Ensayos Fase I

    Madrid, 28040, Spain

  • Hospital Universitario Quirón-Dexeus Servicio de Oncologia Médica

    Barcelona, 08028, Spain

  • Hospital Universitario Virgen de la Arrixaca. Servicio de Oncología Ctra. Madrid-Cartagena, s/n

    Murcia, 30120, Spain

  • Lancashire Teaching Hospitals NHS Foundation Trust

    Preston, Lancashire, PR2 9HT, United Kingdom

  • McGill University Health Care

    Montreal, Quebec, H4A 3J1, Canada

  • Robert H.Lurie ComprehensiveCancer Center, Northwestern University

    Chicago, Illinois, 60611, United States

  • START Midwest

    Grand Rapids, Michigan, 49546, United States

  • Stephenson Cancer Center, OU Health/ Sarah Cannon Research Institute

    Oklahoma City, Oklahoma, 73104, United States

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, SM2 5PT, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, W1T 7HA, United Kingdom

  • University health Network (UHN)-University of Toronto

    Toronto, Ontario, M5G 2M9, Canada

  • University of Arkansas for Medical sciences

    Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.